Navigation Links
A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
Date:7/29/2008

Crestor Will Remain the Clinical Gold Standard Drug Through 2016, According

to a New Report from Decision Resources

WALTHAM, Mass., July 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that raises high-density lipoprotein cholesterol and has a lower discontinuation rate than that of Abbott's Niaspan ER (extended release) would earn a 20 percent patient share in the treatment of dyslipidemia, according to surveyed endocrinologists.

The new report entitled Dyslipidemia: Blockbuster Potential for Agents that Target HDL finds that although lowering low-density lipoprotein cholesterol levels is at the forefront of treating dyslipidemia, researchers are now aware that increasing high-density lipoprotein cholesterol levels may also help reduce cardiovascular risk.

The report also finds that surveyed endocrinologists do not expect any therapy under development to displace AstraZeneca's Crestor as the Decision Resources' proprietary clinical gold standard for dyslipidemia through 2016. Although some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with Crestor.

"For the majority of end points, endocrinologists we surveyed perceive the statin class to be very similar," said Graeme Green, Ph.D., analyst at Decision Resources. "However Crestor positively differentiates itself in its greater ability to improve low- and high-density lipoprotein cholesterol levels."

About the Report

Dyslipidemia: Blockbuster Potential for Agents that Target HDL is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign
2. Cost of raising a child with special needs: Where does your state rank?
3. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Indianapolis is Participating
4. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Cincinnati is Participating
5. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Texas Participating
6. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in New Jersey Participating
7. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Minnesota Participating
8. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Michigan Participating
9. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Colorado Participating
10. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in California Participating
11. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: